Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012)

Ptc Therapeutics (PTCT) posted quarterly Preferred Stock Liabilities of $80.8 million for Q4 2012.

Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012) Analysis & Trends

Ptc Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $80.8 million for Q4 2012.

In Q4 2012, Preferred Stock Liabilities changed N/A year-over-year to $80.8 million; the TTM figure through Dec 2012 stood at $80.8 million (changed N/A YoY), while the FY2012 annual figure was $80.8 million, down 62.3% from the prior year.
Preferred Stock Liabilities for Q4 2012 stood at $80.8 million.
The five-year high for Preferred Stock Liabilities was $80.8 million in Q4 2012, with the low at $80.8 million in Q4 2012.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Ptc Therapeutics	5.97 Bn	3.75 Bn	340.60 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2012	80.82 Mn